First discovered as a genome-editing tool just seven years ago, CRISPR systems have already changed the face of basic research, allowing researchers to alter the DNA of hundreds of organisms for research purposes. As the technology advances, real-world applications are on the horizon– the first clinical trials to treat genetic diseases with CRISPR have begun this year, and the first genome-edited crop is scheduled for commercial release in 2020. With such rapid advancement, how do the products of CRISPR technology fit into the current regulatory system? This talk will give an overview of US biotechnology policy and regulation with a focus on biotech plants. It will compare approaches to regulating GMOs, and ask, how can this history and social context help us think about what is needed for this new generation of genome-edited organisms?
Molecular Biology
Genomics
Bioinformatics
Molecular Diagnostics
Dna
Pcr/rt-Pcr/real-Time Pcr
Assay Development
Animal Research
Lab Automation
Clinical Research
Gene Expression
Cell Culture
Laboratory Testing
Crispr
Gene Sequencing
North America57%
Asia14%
Europe14%
South America14%
Website Visitors86%
Email Promotions14%
Educator/Faculty33%
Medical Laboratory Technician33%
Student17%
Engineer17%
Academic Institution57%
Biotech Company29%
Clinical Laboratory14%